6.9101
price down icon9.87%   -0.7899
 
loading
Schlusskurs vom Vortag:
$7.70
Offen:
$7.6
24-Stunden-Volumen:
156.90K
Relative Volume:
1.37
Marktkapitalisierung:
$861.22M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-4.6067
EPS:
-1.5
Netto-Cashflow:
$-171.05M
1W Leistung:
-22.74%
1M Leistung:
-4.60%
6M Leistung:
-57.13%
1J Leistung:
-86.78%
1-Tages-Spanne:
Value
$6.75
$7.60
1-Wochen-Bereich:
Value
$6.75
$10.25
52-Wochen-Spanne:
Value
$6.4725
$70.75

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name
Firmenname
Mersana Therapeutics Inc
Name
Telefon
617-498-0020
Name
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Name
Mitarbeiter
102
Name
Twitter
@MersanaADC
Name
Nächster Verdiensttermin
2025-03-03
Name
Neueste SEC-Einreichungen
Name
MRSN's Discussions on Twitter

Vergleichen Sie MRSN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MRSN
Mersana Therapeutics Inc
6.9101 38.39M 36.86M -171.67M -171.05M -1.50
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.15 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.30 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.78 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.97 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
297.91 31.54B 3.81B -644.79M -669.77M -6.24

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-06 Eingeleitet William Blair Outperform
2024-11-15 Fortgesetzt Citigroup Buy
2024-03-19 Hochstufung JP Morgan Underweight → Neutral
2024-02-29 Hochstufung BTIG Research Neutral → Buy
2024-02-29 Hochstufung Guggenheim Neutral → Buy
2024-02-29 Hochstufung Wedbush Neutral → Outperform
2023-12-04 Hochstufung Citigroup Neutral → Buy
2023-07-28 Herabstufung Robert W. Baird Outperform → Neutral
2023-07-27 Herabstufung BTIG Research Buy → Neutral
2023-07-27 Herabstufung Citigroup Buy → Neutral
2023-07-27 Herabstufung Guggenheim Buy → Neutral
2023-07-27 Herabstufung JP Morgan Neutral → Underweight
2023-07-27 Herabstufung Truist Buy → Hold
2023-07-27 Herabstufung Wedbush Outperform → Neutral
2023-06-16 Herabstufung JP Morgan Overweight → Neutral
2023-06-15 Eingeleitet Guggenheim Buy
2023-03-16 Hochstufung JP Morgan Neutral → Overweight
2023-01-20 Eingeleitet Citigroup Buy
2022-11-21 Eingeleitet Truist Buy
2021-10-15 Fortgesetzt BTIG Research Buy
2021-08-30 Eingeleitet H.C. Wainwright Buy
2021-03-31 Eingeleitet Credit Suisse Neutral
2020-12-03 Eingeleitet Stifel Buy
2020-09-29 Fortgesetzt JP Morgan Neutral
2020-04-29 Eingeleitet BTIG Research Buy
2020-01-21 Bestätigt H.C. Wainwright Buy
2019-03-11 Herabstufung JP Morgan Neutral → Underweight
2018-11-14 Hochstufung Leerink Partners Mkt Perform → Outperform
2018-05-08 Eingeleitet Robert W. Baird Outperform
2018-03-19 Herabstufung JP Morgan Overweight → Neutral
Alle ansehen

Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten

pulisher
Jul 27, 2025

What is Mersana Therapeutics Inc. company’s growth strategyRapid profit acceleration - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Should I hold or sell Mersana Therapeutics Inc. stock in 2025Exceptional stock performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Mersana Therapeutics Inc.Maximize returns with disciplined trading approaches - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Does Mersana Therapeutics Inc. stock perform well during market downturnsBreakthrough capital growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Why Mersana Therapeutics Inc. stock attracts strong analyst attentionControlled Risk High Reward Plan - Metal.it

Jul 27, 2025
pulisher
Jul 26, 2025

How Mersana Therapeutics Inc. stock performs during market volatilityTop Growth Low Risk Stocks - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

MRSN Trading Halted Due to Pending News - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Mersana Therapeutics Inc. stockSuperior stock selection - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025 - Insider Monkey

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Mersana Therapeutics Inc. stock priceRapid wealth accumulation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Will Mersana Therapeutics Inc. stock split in the near futureFree Investment Case Studies - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics to execute 1-for-25 reverse stock split - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana To Implement 1-for-25 Reverse Stock Split To Regain Nasdaq Compliance - Nasdaq

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics Implements Reverse Stock Split to Meet Nasdaq Listing Requirements - AInvest

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan - Investing.com Australia

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan By Investing.com - Investing.com South Africa

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics to implement 1-for-25 reverse stock split Friday - Investing.com Australia

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics to implement 1-for-25 reverse stock split Friday By Investing.com - Investing.com South Africa

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics (MRSN) Implements 1-for-25 Reverse Stock Sp - GuruFocus

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics Announces Reverse Stock Split - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics to implement 1-for-25 reverse stock split - Investing.com India

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics to implement 1-for-25 reverse stock split By Investing.com - Investing.com Nigeria

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana (MRSN) Announces 1-for-25 Reverse Split to Retain Nasdaq Listing - Stock Titan

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewswire

Jul 24, 2025
pulisher
Jul 24, 2025

Mersana's 1:25 Reverse Split Aims to Save Nasdaq Listing: Key Details for Investors - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

Mersana Therapeutics Inc. Stock Analysis and ForecastSuperior stock growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

MRSN: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com

Jul 23, 2025
pulisher
Jul 23, 2025

12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

Is Mersana Therapeutics Inc. a good long term investmentPowerful growth strategies - jammulinksnews.com

Jul 23, 2025

Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Mersana Therapeutics Inc-Aktie (MRSN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Mandelia Ashish
VP, Chief Accounting Officer
Jan 16 '25
Sale
0.58
3,554
2,061
57,519
Protopapas Anna
Director
Jan 15 '25
Option Exercise
0.00
21,250
0
176,678
Protopapas Anna
Director
Jan 16 '25
Sale
0.58
8,637
5,009
168,041
Lowinger Timothy B
SVP, Chief Sci.&Tech. Officer
Jan 15 '25
Option Exercise
0.00
19,791
0
265,721
Lowinger Timothy B
SVP, Chief Sci.&Tech. Officer
Jan 16 '25
Sale
0.58
8,048
4,668
257,673
Huber Martin H. Jr.
President, CEO
Jan 15 '25
Option Exercise
0.00
11,062
0
127,389
Huber Martin H. Jr.
President, CEO
Jan 16 '25
Sale
0.58
4,514
2,618
122,875
DeSchuytner Brian
SVP, COO & CFO
Jan 15 '25
Option Exercise
0.00
20,833
0
129,863
DeSchuytner Brian
SVP, COO & CFO
Jan 16 '25
Sale
0.58
8,470
4,913
121,393
Carvajal Alejandra
SVP, Chief Legal Officer
Jan 15 '25
Option Exercise
0.00
12,500
0
83,392
$23.26
price down icon 0.53%
$37.03
price up icon 1.02%
$103.59
price down icon 0.34%
$27.86
price down icon 2.90%
$113.62
price down icon 1.31%
biotechnology ONC
$297.90
price up icon 2.17%
Kapitalisierung:     |  Volumen (24h):